Advertisement

Topics

70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvements in PSA Doubling Time

09:19 EST 12 Jan 2018 | Speciality Pharma Journal

BATON ROUGE, La., Jan. 10, 2018 (GLOBE NEWSWIRE) — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, today announces the latest follow-up data from the Company’s Phase 1a trial of ProscaVax for prostate cancer.  ProscaVax is …

Original Article: 70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvements in PSA Doubling Time

NEXT ARTICLE

More From BioPortfolio on "70% of Advanced Prostate Cancer Patients Treated with ProscaVax Demonstrate Improvements in PSA Doubling Time"

Quick Search
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...